XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced today that XTANDI®...

Related Keywords

Japan ,Canada ,United States ,Tokyo ,America ,American ,Naoki Okamura ,Exchange Commission ,Medivation Inc ,Lab Abnormalities ,European Union ,Astellas Inc ,Pfizer Inc ,American Society Of Clinical Oncology ,Astellas Pharma Inc ,Prnewswire Astellas Pharma Inc ,Pfizer ,American Urological Association Annual Meeting ,Urological Association Annual ,Hazard Ratio ,Confidence Interval ,Pfizer Led Phase ,South America ,Non Metastatic Hormone Sensitive Prostate Cancer ,High Risk Biochemical Recurrence ,Reversible Encephalopathy Syndrome ,Heart Disease ,Fetal Toxicity ,Drug Interactions ,Full Prescribing Information ,Focus Area Approach ,Pfizer Oncology ,Astellas Pharma ,Annual Report ,Looking Information ,Factors That May Affect Future ,Accessed March ,Prostate Cancer ,Clin Pract ,North America ,Pharma Inc ,Astellas Pharma Inc Pfizer ,